Compare Novartis AG (NVS) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Rocket Lab USA Inc — how do they compare? Novartis AG trades at $139 (market cap $262.64B), while Rocket Lab USA Inc trades at $63.25 (market cap $42.12B). The key difference: Novartis AG is far larger — about 6.2× Rocket Lab USA Inc's market cap, and Novartis AG pays a 3.44% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.
| NVS | RKLB | |
|---|---|---|
Market Cap | $262.64B | $42.12B |
Sector | Health | Technology |
52-Week High | $168.62 | $150.23 |
52-Week Low | $121.80 | $39.48 |
Enterprise Value | $303.97B | $39.95B |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Rocket Lab (RKLB) trades at $65.87, up 2.51% on the day, but remains in a bearish technical trend below key resistance levels. The company reported record Q2 2026 revenue of $234 million, up 62% year-over-year, yet continues to post significant net losses. Recent news highlights progress on the Neutron rocket and the pending Iridium Communications acquisition, but investor sentiment is mixed due to execution risks and delays.
The outlook hinges on successful Neutron deployment and path to profitability. Analysts see substantial upside with a $117.44 consensus target, but risks include cash burn, competitive pressure, and potential further launch delays. The stock offers high-growth potential for risk-tolerant investors betting on the space economy's expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
